Literature DB >> 10222105

Recent advances on the pathogenesis of Huntington's disease.

A Petersén1, K Mani, P Brundin.   

Abstract

We review recent advances regarding the pathogenesis of Huntington's disease (HD). This genetic neurodegenerative disorder is caused by an expanded CAG repeat in a gene coding for a protein, with unknown function, called huntingtin. There is selective death of striatal and cortical neurons. Both in patients and a transgenic mouse model of the disease, neuronal intranuclear inclusions, immunoreactive for huntingtin and ubiquitin, develop. Huntingtin interacts with the proteins GAPDH, HAP-1, HIP1, HIP2, and calmodulin, and a mutant huntingtin is specifically cleaved by the proapoptotic enzyme caspase 3. The pathogenetic mechanism is not known, but it is presumed that there is a toxic gain of function of the mutant huntingtin. Circumstantial evidence suggests that excitotoxicity, oxidative stress, impaired energy metabolism, and apoptosis play a role. Copyright 1999 Academic Press.

Entities:  

Mesh:

Year:  1999        PMID: 10222105     DOI: 10.1006/exnr.1998.7006

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  25 in total

1.  The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription.

Authors:  J S Steffan; A Kazantsev; O Spasic-Boskovic; M Greenwald; Y Z Zhu; H Gohler; E E Wanker; G P Bates; D E Housman; L M Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

Review 2.  Huntington's disease.

Authors:  S Davies; D B Ramsden
Journal:  Mol Pathol       Date:  2001-12

3.  Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease.

Authors:  Korrapati V Sathyasaikumar; Erin K Stachowski; Laura Amori; Paolo Guidetti; Paul J Muchowski; Robert Schwarcz
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

4.  Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6/2 mouse model of Huntington's disease.

Authors:  Ying Dai; Nichole L Dudek; Qian Li; Stephen C Fowler; Nancy A Muma
Journal:  J Neurosci       Date:  2009-09-16       Impact factor: 6.167

5.  Synchrotron infrared microspectroscopy detecting the evolution of Huntington's disease neuropathology and suggesting unique correlates of dysfunction in white versus gray brain matter.

Authors:  Markus Bonda; Valérie Perrin; Bertrand Vileno; Heike Runne; Ariane Kretlow; László Forró; Ruth Luthi-Carter; Lisa M Miller; Sylvia Jeney
Journal:  Anal Chem       Date:  2011-09-22       Impact factor: 6.986

6.  Tissue-specific proteolysis of Huntingtin (htt) in human brain: evidence of enhanced levels of N- and C-terminal htt fragments in Huntington's disease striatum.

Authors:  L M Mende-Mueller; T Toneff; S R Hwang; M F Chesselet; V Y Hook
Journal:  J Neurosci       Date:  2001-03-15       Impact factor: 6.167

7.  Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice.

Authors:  Edgardo Rodriguez-Lebron; Eileen M Denovan-Wright; Kevin Nash; Alfred S Lewin; Ronald J Mandel
Journal:  Mol Ther       Date:  2005-10       Impact factor: 11.454

8.  Ca2+-induced permeability transition in human lymphoblastoid cell mitochondria from normal and Huntington's disease individuals.

Authors:  Alexander V Panov; Serena Lund; J Timothy Greenamyre
Journal:  Mol Cell Biochem       Date:  2005-01       Impact factor: 3.396

9.  Inhibition of p38 Mitogen-Activated Protein Kinase Ameliorates HAP40 Depletion-Induced Toxicity and Proteasomal Defect in Huntington's Disease Model.

Authors:  Zih-Ning Huang; Jie-Mao Chen; Liang-Ching Huang; Yi-Hsuan Fang; Lu-Shiun Her
Journal:  Mol Neurobiol       Date:  2021-01-25       Impact factor: 5.590

10.  Cytochrome C and caspase-9 expression in Huntington's disease.

Authors:  Tamara Kiechle; Alpaslan Dedeoglu; James Kubilus; Neil W Kowall; M Flint Beal; Robert M Friedlander; Steven M Hersch; Robert J Ferrante
Journal:  Neuromolecular Med       Date:  2002       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.